Details of the BTS
General Information of Binding Target of SBP (BTS) (ID: ST00108) | ||||||
---|---|---|---|---|---|---|
BTS Name |
Tyrosine-protein kinase ABL1
|
|||||
Synonyms |
EC 2.7.10.2; Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150
|
|||||
BTS Type |
Protein
|
|||||
Family |
Protein kinase superfamily;
Tyr protein kinase family; ABL subfamily |
|||||
Gene Name |
ABL1
|
|||||
Organism |
Homo sapiens (Human)
|
|||||
Function |
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner. Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity).
|
|||||
UniProt ID | ||||||
UniProt Entry | ||||||
PFam | ||||||
Gene ID | ||||||
Sequence |
MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSE
NDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVN SLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTAS DGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERT DITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQ LLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFI HRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKS DVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNP SDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAE HRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLF SALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSP KPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSAS CVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTV TPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGS ALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPP PPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVL PATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPE RIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNK FAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR |
|||||
Sequence Length |
1130
|
|||||
Synthetic Binding Protein (SBP) Targeting This BTS |
---|
SBP Name | Highest Status | Mechanism | Affinity | Application | Details | Ref |
---|---|---|---|---|---|---|
Cyclotide anti-Abl MTAbl06 | Research | Inhibitor | N.A. | Chronic myeloid leukaemia [ICD-11: 2B33.2] | [1] | |
Cyclotide anti-Abl MTAbl07 | Research | Inhibitor | N.A. | Chronic myeloid leukaemia [ICD-11: 2B33.2] | [1] | |
Cyclotide anti-Abl MTAbl13 | Research | Inhibitor | N.A. | Chronic myeloid leukaemia [ICD-11: 2B33.2] | [1] | |
Monobody anti-Abl HA4 | Research | Inhibitor | Kd: 7 nM | Research tool | [2], [3], [4] | |
Monobody anti-Abl-SH2 7c12 | Research | Inhibitor | Kd: 50 nM | Research tool | [5], [6], [7] | |
Monobody anti-Abl-SH2 AL2 | Research | Binder | Kd: 70 nM | Tools for identifying the unanticipated mode of monobody-target interactions | [7] | |
Monobody anti-Abl-SH2 AL38 | Research | Binder | Kd: 11 nM | Tools for identifying the unanticipated mode of monobody-target interactions | [7] | |
Monobody anti-Abl-SH2 AS15 | Research | Binder | Kd: 9 nM | Tools for identifying the unanticipated mode of monobody-target interactions | [7] | |
Monobody anti-Abl-SH2 AS25 | Research | Inhibitor | Kd: 20 nM | Research tool | [5], [6], [7] | |
Monobody anti-Abl-SH2 AS27 | Research | Inhibitor | Kd: 3.7 nM | Research tool | [5], [6], [7] | |
Monobody anti-Abl-SH2 GG10 | Research | Inhibitor | Kd: 900 nM | Chronic myeloid leukaemia [ICD-11: 2B33.2] | [6] | |
Monobody anti-Abl-SH2 GG3 | Research | Inhibitor | Kd: 2540 nM | Chronic myeloid leukaemia [ICD-11: 2B33.2] | [6] | |
Monobody anti-Abl-SH2 HA10 | Research | Inhibitor | N.A. | Research tool | [3], [8] | |
Monobody anti-Abl-SH2 HA16 | Research | Inhibitor | N.A. | Research tool | [3], [8] | |
Monobody anti-Abl-SH2 HA18 | Research | Inhibitor | N.A. | Research tool | [3], [8] | |
Monobody anti-Abl-SH2 SH13 | Research | Binder | Kd: 6800 nM | Tools for identifying the unanticipated mode of monobody-target interactions | [7] | |
References |
---|